Archived News

This site is a B2B information site for professional use - clinical diagnostics products listed are for Research Use Only unless otherwise stated.

Charles River Microbial Solutions Celsis Innovation that works as hard as you do

Download Infographic about Pharmaceutical Sterility Testing with Growth Direct Rapid System

rapidmicrobiology special focus on automation and ergonomics for the microbiology lab

Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II

go back to news archives

Abbott announced that it has received approval from the U.S. Food and Drug Administration for its fully automated HTLV-I/HTLV-II blood screening test for use on the ABBOTT PRISM instrument. The test is intended for use by laboratories to screen individual donations of blood and plasma for antibodies to human T -- lymphotropic virus Type I and/or human T -- lymphotropic virus Type II (anti-HTLV-I/HTLV-II).

HTLV-I and HTLV-II are closely related but distinct retroviruses associated with several diseases including human T-cell leukemia and neurological disorders, according to the Centers for Disease Control. Screening of the U.S. blood supply for HTLV-I/II began in 1988.

Used in more than 30 countries, the PRISM system also includes four hepatitis tests: a core hepatitis B test (PRISM HBcore), introduced in October 2005; two hepatitis B surface antigen tests (PRISM HBsAg and HBsAg Confirmatory), introduced in July 2006; and a hepatitis C test (PRISM HCV), introduced in July 2007.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Abbott Laboratories View Company Information

Posted on January 23, 2008